Pharmacologic class: Lipoglyco-peptide

Therapeutic class: Anti-infective

Pregnancy risk category C

GI: nausea, vomiting, diarrhea, abdominal pain, taste disturbance, Clostridium difficile-associated diarrhea

FDA Box Warning

Women of childbearing age should have serum pregnancy test before receiving telavancin.

Avoid using telavancin during pregnancy unless potential benefit to patient outweighs potential risk to fetus.

Adverse developmental outcomes observed in three animal species at clinically relevant doses raise concerns about potential adverse developmental outcomes in humans.


Binds to bacterial membrane and disrupts membrane barrier function


Injection: 250 mg, 750 mg in single-use vials

Indications and dosages

Complicated skin and skin-structure infections caused by susceptible gram-positive bacteria

Adults: 10 mg/kg I.V infusion over 60 minutes q 24 hours for 7 to 14 days

Dosage adjustment

• Renal impairment




Use cautiously in:

• renal impairment

• concurrent use of drugs known to prolong QT interval

• history of congenital long QT syndrome, known prolongation of QTc interval, uncompensated heart failure, severe left ventricular hypertrophy (avoid use)

• elderly patients

• pregnant or breastfeeding patients

• children (safety and efficacy not established).


• Obtain renal function studies before starting therapy.

• Administer slowly (over 60 minutes) to reduce risk of infusion-related reactions.

• Although drug doesn't interfere with coagulation, it does, shortly after completion of infusion, interfere with certain tests used to monitor coagulation, such as prothrombin time (PT), International Normalized Ratio (INR), activated partial thromboplastin time (aPTT), activated clotting time, and coagulation-based factor Xa tests. Don't collect blood samples for such assays immediately or shortly after infusion completion because such effects dissipate as telavancin concentration decreases.

Adverse reactions

CNS: dizziness

CV: cardiac events

GI: nausea, vomiting, diarrhea, abdominal pain, taste disturbance, Clostridium difficile-associated diarrhea

GU: foamy urine, renal events, nephrotoxicity

Respiratory: respiratory events

Skin: rash, pruritus, infusion-site erythema

Other: rigors, decreased appetite, infectious events, superinfection, infusion-site pain, infusion reactions


Drug-diagnostic tests. Activated clotting time, aPTT, coagulation-based factor Xa tests, INR, PT; urine qualitative protein assays: interference with results

Patient monitoring

Be aware that new-onset or worsening renal impairment has occurred in patients taking telavancin. Monitor renal function at 48- and 72-hour intervals during treatment, or more frequently if clinically indicated, and at end of therapy.

Watch for C. difficile-associated diarrhea, which may range in severity from mild diarrhea to fatal colitis; consider discontinuing drug if C. difficile-associated diarrhea occurs.

• Watch for "red-man" syndrome, which can result from rapid infusion. Signs and symptoms include flushing of upper body, hypotension, pruritus, and maculopapular rash on face, neck, trunk, and limbs.

Patient teaching

Instruct patient to tell prescriber if severe diarrhea occurs.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


(tel-a-van-sin) ,


(trade name)


Therapeutic: anti infectives
Pharmacologic: lipoglycopeptides
Pregnancy Category: C


Treatment of complicated skin/skin structure infections caused by susceptible bacteria.Hospital-acquired and ventilator-associated bacterial pneumonia caused by Staphylococcus aureus


Inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptidoglycan.

Therapeutic effects

Bactericidal action against susceptible organisms.
Active against Staphylococcus aureus (including methicillin-susceptible and -resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin-susceptible strains only).


Absorption: IV administration results in complete bioavailability.
Distribution: Penetrates blister fluid.
Metabolism and Excretion: Metabolism is not known; 76% excreted unchanged in urine <1% in feces.
Half-life: 8 hr.

Time/action profile

IVunknownend of infusion24 hr


Contraindicated in: HypersensitivityCongenital long QT syndrome, known prolongation of the QT interval, uncompensated HF, or severe left ventricular hypertrophy (risk of fatal arrhythmias); Obstetric: Do not use unless potential maternal benefit outweighs potential risk to fetus.
Use Cautiously in: Renal impairment (efficacy may be ↓; dose ↓ recommended for CCr ≤50 mL/min) (↑ risk of mortality in patients with CCr ≤50 mL/min; use only if benefit outweighs risk) (↑ risk of renal impairment);Diabetes, HF, hypertension (↑ risk of renal impairment) Geriatric: Consider age-related ↓ in renal function, adjust dose accordingly (↑ risk of adverse renal reactions); Lactation: Use cautiously; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • dizziness


  • QT interval prolongation


  • pseudomembranous colitis (life-threatening)
  • taste disturbance (most frequent)
  • nausea (most frequent)
  • vomiting (most frequent)
  • abdominal pain


  • foamy urine (most frequent)
  • nephrotoxicity


  • anaphylaxis (life-threatening)
  • infusion reactions


Drug-Drug interaction

Concurrent use of other medications known to prolong QT interval may ↑ risk of arrhythmias.Concurrent use of NSAIDs, ACE inhibitors, and loop diuretics may ↑ risk of adverse renal effects.


Complicated Skin/Skin Structure Infections

Intravenous (Adults) 10 mg/kg ever 24 hr for 7–14 days.

Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia

Intravenous (Adults) 10 mg/kg ever 24 hr for 7–21 days.

Renal Impairment

Intravenous (Adults) CCr 30–50 mL/min—7.5 mg/kg every 24 hr; CCr 10–≤30 mL/min—10 mg/kg every 48 hr.


Sterile lyophilized powder for IV use (requires reconstitution): 250 mg/vial, 750 mg/vial

Nursing implications

Nursing assessment

  • Assess for infection (vital signs; appearance of wound, sputum, urine, and stool; WBC) at beginning of and throughout therapy.
  • Obtain specimens for culture and sensitivity prior to therapy. First dose may be given before receiving results.
  • Assess women of child bearing age for pregnancy. Women should have a negative serum pregnancy test before starting telavancin.
  • Monitor bowel function. Diarrhea, abdominal cramping, fever, and bloody stools should be reported to health care professional promptly as a sign of pseudomembranous colitis. May begin up to several weeks following cessation of therapy.
  • Monitor for infusion reactions (Red-man syndrome—flushing of upper body, urticaria, pruritus, rash). May resolve with stopping or slowing infusion.
  • Observe patient for signs and symptoms of anaphylaxis (rash, pruritus, laryngeal edema, wheezing). Discontinue drug and notify health care professional immediately if symptoms occur. Keep epinephrine, an antihistamine, and resuscitation equipment close by in case of anaphylactic reaction.
  • Lab Test Considerations: Monitor renal function (serum creatinine. creatinine clearance) prior to, every 48–72 hrs during, and at the end of therapy. May cause nephrotoxicity. If renal function decreases, reassess need for telavancin.
    • May interfere with prothrombin time, INR, aPTT, activated clotting time, and coagulation based factor Xa tests. Collect blood samples for theses tests as close to next dose of telavancin as possible.
    • Interferes with urine qualitative dipstick protein assays and quantitative dye methods; may use microalbumin assays.

Potential Nursing Diagnoses

Risk for infection (Indications)
Diarrhea (Adverse Reactions)


  • Intravenous Administration
  • Intermittent Infusion: Reconstitute the 250 mg vial with 15 mL and the 750 mg vial with 45 mL of D5W, sterile water for injection, or 0.9% NaCl for concentrations of 15 mg/mL. Reconstitution time is usually under 2 min but may require up to 20 min. Mix thoroughly with contents dissolved completely. Do not administer solution that is discolored or contains particulate matter. Discard vial if vacuum did not pull diluent into vial. Time in vial plus time in bag should not exceed 4 hr at room temperature or 72 hr if refrigerated. Diluent: For doses of 150–800 mg dilute further with 100–250 mL of D5W, 0.9% NaCl, or LR.Concentration: For doses <150 mg or >800 mg dilute for a final concentration of 0.6–8 mg/mL.
  • Rate: Administer over at least 60 min to minimize infusion reactions.
  • Y-Site Incompatibility: Do not mix or administer with other medications. Flush line with D5W, 0.9% NaCl, or LR before and after administration.
  • Y-Site Compatibility: amphotericin B lipid complex, ampicillin/sulbactam, azithromycin, calcium gluconate, caspofungin, cefepime, ceftazidime, ceftriaxone, ciprofloxacin, dexamethasone, diltiazem, dobutamine, dopamine, doripenem, doxycycline, ertapenem, famotidine, fluconazole, gentamicin, hydrocortisone, labetalol, magnesium sulfate, mannitol, meropenem, metoclopramide, milrinone, norepinephrine, ondansetron, pantoprazole, phenylephrine, piperacillin/tazobactam, potassium chloride, potassium phosphates, ranitidine, sodium bicarbonate, sodium phosphates, tigecycline, tobramycin, vasopressin
  • Y-Site Incompatibility: amphotericin B colloidal, amphotericin B liposome, digoxin, esomeprazole, furosemide, levofloxacin, micafungin

Patient/Family Teaching

  • Instruct patient to notify health care professional immediately if diarrhea, abdominal cramping, fever, or bloody stools occur and not to treat with antidiarrheals without consulting health care professionals.
  • Inform patient that common side effects include taste disturbance, nausea, vomiting, headache and foamy urine. Notify health care professional if signs of infusion reaction occur.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
  • Advise female patients to use effective contraception during therapy and to notify health care professional if pregnancy is suspected. Encourage pregnant patients to enroll in the VIBATIV pregnancy registry by calling 1-888-658-4228.
  • Instruct the patient to notify health care professional if symptoms do not improve.

Evaluation/Desired Outcomes

  • Resolution of the signs and symptoms of infection. Length of time for complete resolution depends on the organism and site of infection.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
Vibativ is contraindicated in patients with a known hypersensitivity to telavancin.
All isolates were susceptible to daptomycin, linezolid, telavancin, and vancomycin.
Vibativ (telavancin, injection) was discovered in a research programme dedicated to finding new antibiotics for serious infections due to Staphylococcus aureus (S.
Two presentations were made reporting new data from the ongoing Telavancin Observational Use Registry study, which is designed to report how VIBATIV is being used by healthcare practitioners to treat patients in real-world clinical settings.
Vancomycin, teicoplanin and telavancin are few examples of such compounds [1].
Additional agents with activity against coagulase-negative staphylococci and MRSA include daptomycin, tedizolid, telavancin, dalba-vancin, oritavancin, ceftaroline, and quinupristin-dalfopristin.
M2 PHARMA-April 25, 2018-Results from Multiple Studies of Vibativ (telavancin) Presented at 2018 ECCMID Conference
Alternative drugs for bloodstream infections caused by MRSA have been released, including telavancin, dalbavancin, oritavancin, and daptomycin; however, these options are not affordable in some developing countries [11].
(3,4) Some MRSA have been discovered resistant to new antibiotics such as linezolid, quinupristin/ dalfopristin, daptomycin and telavancin (5-7) which has limited the drug's effectiveness.
Skin and soft-tissue infections: A critical review and the role of telavancin in their treatment.
For example, a study about bidirectional placental transfer of antibiotics revealed that telavancin had a higher placental transfer in the reverse direction, suggesting that a translocation occurred by means other than passive diffusion and indicating that specific transporters may be involved (Nanovskaya et al.